Details for New Drug Application (NDA): 218549
✉ Email this page to a colleague
The generic ingredient in ZUNVEYL is benzgalantamine gluconate. One supplier is listed for this compound. Additional details are available on the benzgalantamine gluconate profile page.
Summary for 218549
Tradename: | ZUNVEYL |
Applicant: | Alpha Cognition |
Ingredient: | benzgalantamine gluconate |
Patents: | 2 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 218549
Generic Entry Date for 218549*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET, DELAYED RELEASE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Suppliers and Packaging for NDA: 218549
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
ZUNVEYL | benzgalantamine gluconate | TABLET, DELAYED RELEASE;ORAL | 218549 | NDA | Alpha Cognition, Inc. | 84054-005 | 84054-005-60 | 60 TABLET, DELAYED RELEASE in 1 BOTTLE (84054-005-60) |
ZUNVEYL | benzgalantamine gluconate | TABLET, DELAYED RELEASE;ORAL | 218549 | NDA | Alpha Cognition, Inc. | 84054-010 | 84054-010-60 | 60 TABLET, DELAYED RELEASE in 1 BOTTLE (84054-010-60) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, DELAYED RELEASE;ORAL | Strength | EQ 5MG BASE | ||||
Approval Date: | Jul 26, 2024 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Jan 13, 2042 | Product Flag? | Substance Flag? | Y | Delist Request? | ||
Patented Use: | TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | May 16, 2027 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, DELAYED RELEASE;ORAL | Strength | EQ 10MG BASE | ||||
Approval Date: | Jul 26, 2024 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Jan 13, 2042 | Product Flag? | Substance Flag? | Y | Delist Request? | ||
Patented Use: | TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE |
Complete Access Available with Subscription